A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
ACTRIMS
Multiple Sclerosis News Today is providing virtual coverage of the ACTRIMS Forum 2026, taking place Feb. 5-7 in San Diego. Stay tuned to this page for all the latest news.
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, a three-day meeting focused on multiple sclerosis (MS) research and care. ACTRIMS 2026, being held Feb. 5-7 at the Marriott Marquis San Diego…
Recommended Posts
- ACTRIMS 2026: ULTIMATE trial testing Briumvi in kids with MS to launch soon
- ACTRIMS 2026: Vidofludimus calcium targets key MS mechanisms, data show
- ACTRIMS 2026: Current exercise habits linked to lower disability in MS: Study
- ACTRIMS 2026: Bazedoxifene fails to boost myelin repair in women with MS
- ACTRIMS 2026: New study questions whether EBV precedes every MS case